Serum Protein Profiling to Characterize Patient Risk in Men Undergoing Radical Prostatectomy

Trial Information

Serum Protein Profiling to Characterize Patient Risk in Men Undergoing Radical Prostatectomy

In this pilot study, we propose to address the question: is there a small peptide mass
proteomic profile/pattern in blood that can distinguish men with a clinically
insignificant/latent prostate cancer from men with more advanced pathological features? We
will obtain a pre-operative blood sample from men with clinically localized prostate cancer
undergoing radical prostatectomy and determine their preoperative small peptide mass
proteomic profile. The pathological features of the radical prostatectomy will be determined
and the patient will be classified as having either a pathologically insignificant/latent
prostate cancer or a significant cancer. We will then analyze whether or not the small
peptide mass proteomic profile in blood can distinguish these groups before radical
prostatectomy. In addition, each of these patients will have a blood sample collected at
least 6 weeks to 12 months after surgery to evaluate and compare changes that occur as a
result of radical prostatectomy. This will determine the effect of radical prostatectomy on
the small peptide mass proteomic profile in blood and determine if the proteomic profiles in
blood collected prior to radical prostatectomy can identify men at increased risk for
recurrence.